Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00504270 · ClinicalTrials.gov registry record · Phase 2

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

A Phase 2 study of Psoriasis, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 2
Development phase
66
Enrollment target
15
Study locations

NCT00504270 is a Phase 2 study of Psoriasis that has completed, run by Hoffmann-La Roche. The registered enrollment target is 66 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (86% lower). The trial reports 15 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00504270, a Phase 2 study of Psoriasis, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 2
Development phase
66 participants
Enrollment target
15
Study locations

Study Summary

This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.

Conditions Studied

Psoriasis

Interventions

  • DRUG Placebo
  • DRUG RG3421 120mg
  • DRUG RG3421 20mg

Study Locations (15)

New York

  • - New York
  • - New York
  • - Stony Brook

Texas

  • - Galveston
  • - San Antonio
  • - Webster

Arkansas

  • - Hot Springs
  • - Little Rock

California

  • - Santa Monica

Georgia

  • - Alpharetta

New Jersey

  • - East Windsor

New Mexico

  • - Albuquerque

North Carolina

  • - Winston-Salem

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2007-07
Est. Completion 2009-09
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00504270

The ClinicalTrials.gov registry entry for NCT00504270 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (86% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00504270 reports 15 study locations spanning 10 distinct geographic areas - top geographies include New York, Texas, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00504270 about?

NCT00504270 is a clinical study titled "A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.". This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated t...

What is the current status of trial NCT00504270?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2007-07. Estimated completion is 2009-09.

What conditions does trial NCT00504270 study?

This clinical trial studies the following conditions: Psoriasis.

What interventions are being tested in trial NCT00504270?

The interventions under investigation include: Placebo (DRUG), RG3421 120mg (DRUG), RG3421 20mg (DRUG).

Who is sponsoring clinical trial NCT00504270?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00504270 being conducted?

This trial has 15 study locations across Arkansas, California, Georgia, New Jersey, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Psoriasis

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.